Tanespimycin (KOS-953, 17-AAG)
Updated: Jul 22, 2010
| Brand Name: | |
| Generic Name: | tanespimycin |
| Code Names: | KOS-953, 17-AAG |
| Company: | Bristol-Myers Squibb / Kosan Biosciences |
| FDA Clinical Phase: | clinical development halted |
Description:
A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin. Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells.
Clinical Trials:
For a list of clinical trials studying tanespimycin for the treatment of multiple myeloma, see ClinicalTrials.gov.
Beacon news: BMS Halts Development Of Tanespimycin
Related Articles:
- Could A Decades-Old Antibiotic Have Anti-Myeloma Activity?
- Eyelid-Related Complications Of Velcade Therapy: New Insights And Recommendations
- Selective Digestive Decontamination May Reduce Risk of Infection In Myeloma Patients Undergoing Autologous Stem Cell Transplants
- Adding Clarithromycin To Velcade-Based Myeloma Treatment Regimen Fails To Increase Efficacy While Markedly Increasing Side Effects
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
